Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293399574> ?p ?o ?g. }
- W4293399574 endingPage "1519" @default.
- W4293399574 startingPage "1510" @default.
- W4293399574 abstract "Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in the treatment of MF patients. The primary end point was the proportion of patients with ≥35% reduction in spleen volume (SVR35, proportion of patients with ≥35% reduction in spleen volume) at week 24. The secondary end points included improvement of anemia, rates of symptom response, and safety profile. Between January 8, 2019 and August 29, 2020, 118 patients were recruited and treated with either jaktinib 100 mg BID or 200 mg QD. At week 24, 54.8% (34/62) of patients in the 100 mg BID group and 31.3% (15/48) in the 200 mg QD group achieved SVR35 (p = .0199). Jaktinib treatment increased hemoglobin level to ≥20 g/L in 35.6% (21/59) of patients with hemoglobin ≤100 g/L at baseline. The proportion of patients who achieved a ≥50% improvement in total symptom score at week 24 was 69.6% (39/56) in the BID group and 57.5% (23/40) in the QD group. The most common ≥ grade 3 hematological treatment-emergent adverse events (TEAEs; ≥ 10%) were anemia (100 mg BID: 24.2%, 200 mg QD: 28.8%), thrombocytopenia (16.7%, 11.5%), and neutropenia (3.0%, 11.5%). All non-hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability." @default.
- W4293399574 created "2022-08-28" @default.
- W4293399574 creator A5013018299 @default.
- W4293399574 creator A5016264327 @default.
- W4293399574 creator A5025334650 @default.
- W4293399574 creator A5028634125 @default.
- W4293399574 creator A5035282947 @default.
- W4293399574 creator A5038805449 @default.
- W4293399574 creator A5038893741 @default.
- W4293399574 creator A5044475542 @default.
- W4293399574 creator A5045520699 @default.
- W4293399574 creator A5052274720 @default.
- W4293399574 creator A5052596963 @default.
- W4293399574 creator A5053916580 @default.
- W4293399574 creator A5056570442 @default.
- W4293399574 creator A5057401157 @default.
- W4293399574 creator A5061664113 @default.
- W4293399574 creator A5062310871 @default.
- W4293399574 creator A5062652934 @default.
- W4293399574 creator A5068959729 @default.
- W4293399574 creator A5072458792 @default.
- W4293399574 creator A5074069807 @default.
- W4293399574 creator A5075158998 @default.
- W4293399574 creator A5076538075 @default.
- W4293399574 creator A5084456685 @default.
- W4293399574 creator A5087139691 @default.
- W4293399574 creator A5088192232 @default.
- W4293399574 date "2022-10-04" @default.
- W4293399574 modified "2023-09-26" @default.
- W4293399574 title "Safety and efficacy of jaktinib in the treatment of Janus kinase <scp>inhibitor‐naïve</scp> patients with myelofibrosis: Results of a phase <scp>II</scp> trial" @default.
- W4293399574 cites W1534089060 @default.
- W4293399574 cites W2115351357 @default.
- W4293399574 cites W2121743767 @default.
- W4293399574 cites W2123633897 @default.
- W4293399574 cites W2161021913 @default.
- W4293399574 cites W2405712018 @default.
- W4293399574 cites W2547101781 @default.
- W4293399574 cites W2598479043 @default.
- W4293399574 cites W2754551124 @default.
- W4293399574 cites W2778275419 @default.
- W4293399574 cites W2790003237 @default.
- W4293399574 cites W2791240656 @default.
- W4293399574 cites W2804579795 @default.
- W4293399574 cites W2883135363 @default.
- W4293399574 cites W2970714248 @default.
- W4293399574 cites W2995010510 @default.
- W4293399574 cites W3009670005 @default.
- W4293399574 cites W3012454590 @default.
- W4293399574 cites W3048745234 @default.
- W4293399574 cites W3112678320 @default.
- W4293399574 cites W4293399574 @default.
- W4293399574 doi "https://doi.org/10.1002/ajh.26709" @default.
- W4293399574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36054786" @default.
- W4293399574 hasPublicationYear "2022" @default.
- W4293399574 type Work @default.
- W4293399574 citedByCount "8" @default.
- W4293399574 countsByYear W42933995742022 @default.
- W4293399574 countsByYear W42933995742023 @default.
- W4293399574 crossrefType "journal-article" @default.
- W4293399574 hasAuthorship W4293399574A5013018299 @default.
- W4293399574 hasAuthorship W4293399574A5016264327 @default.
- W4293399574 hasAuthorship W4293399574A5025334650 @default.
- W4293399574 hasAuthorship W4293399574A5028634125 @default.
- W4293399574 hasAuthorship W4293399574A5035282947 @default.
- W4293399574 hasAuthorship W4293399574A5038805449 @default.
- W4293399574 hasAuthorship W4293399574A5038893741 @default.
- W4293399574 hasAuthorship W4293399574A5044475542 @default.
- W4293399574 hasAuthorship W4293399574A5045520699 @default.
- W4293399574 hasAuthorship W4293399574A5052274720 @default.
- W4293399574 hasAuthorship W4293399574A5052596963 @default.
- W4293399574 hasAuthorship W4293399574A5053916580 @default.
- W4293399574 hasAuthorship W4293399574A5056570442 @default.
- W4293399574 hasAuthorship W4293399574A5057401157 @default.
- W4293399574 hasAuthorship W4293399574A5061664113 @default.
- W4293399574 hasAuthorship W4293399574A5062310871 @default.
- W4293399574 hasAuthorship W4293399574A5062652934 @default.
- W4293399574 hasAuthorship W4293399574A5068959729 @default.
- W4293399574 hasAuthorship W4293399574A5072458792 @default.
- W4293399574 hasAuthorship W4293399574A5074069807 @default.
- W4293399574 hasAuthorship W4293399574A5075158998 @default.
- W4293399574 hasAuthorship W4293399574A5076538075 @default.
- W4293399574 hasAuthorship W4293399574A5084456685 @default.
- W4293399574 hasAuthorship W4293399574A5087139691 @default.
- W4293399574 hasAuthorship W4293399574A5088192232 @default.
- W4293399574 hasBestOaLocation W42933995741 @default.
- W4293399574 hasConcept C126322002 @default.
- W4293399574 hasConcept C141071460 @default.
- W4293399574 hasConcept C168563851 @default.
- W4293399574 hasConcept C197934379 @default.
- W4293399574 hasConcept C203092338 @default.
- W4293399574 hasConcept C2777063308 @default.
- W4293399574 hasConcept C2777753580 @default.
- W4293399574 hasConcept C2778248108 @default.
- W4293399574 hasConcept C2778917026 @default.
- W4293399574 hasConcept C2779134260 @default.
- W4293399574 hasConcept C2780007613 @default.
- W4293399574 hasConcept C2780076729 @default.
- W4293399574 hasConcept C29730261 @default.